Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Mild cognitive impairment

Topic: Risk, prevention and care in population studies

The construct of mild cognitive impairment (MCI) has evolved over the past 10 years since the publication of the new MCI definition at the Key Symposium in 2003, but the core criteria have remained unchanged. The construct has been extensively used worldwide, both in clinical and in research settings, to define the grey area between intact cognitive functioning and clinical dementia. A rich set of data regarding occurrence, risk factors and progression of MCI has been generated. Discrepancies between studies can be mostly explained by differences in the operationalization of the criteria, differences in the setting where the criteria have been applied, selection of subjects and length of follow-up in longitudinal studies. Major controversial issues that remain to be further explored are algorithmic versus clinical classification, reliability of clinical judgment, temporal changes in cognitive performances and predictivity of putative biomarkers. Some suggestions to further develop the MCI construct include the tailoring of the clinical criteria to specific populations and to specific contexts. The addition of biomarkers to the clinical phenotypes is promising but requires deeper investigation. Translation of findings from the specialty clinic to the population setting, although challenging, will enhance uniformity of outcomes. More longitudinal population-based studies on cognitive ageing and MCI need to be performed to clarify all these issues.

Key findings

Why it matters

This review looks back on mild cognitive impairment, the "grey area between intact cognitive functioning and clinical dementia," a decade after its 2003 definition, and notes that the core criteria have not changed. It argues that conflicting results between MCI studies are mostly explained by how the criteria are applied, in what setting, to which people and for how long. It lists classification, the reliability of clinical judgement and the predictive value of biomarkers as still unresolved. It reports no new data and no treatment, cure or prevention.

Study details

How this study scored 66/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 7 of 7; Citations per year 5 of 5; Impact for its field and year 6 of 6; Cited by studies here 4 of 6; Still being cited 4 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 66 of 100.66 of 100 points earned34 not earned

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of internal medicine)
Journal's citation record 2 / 4 Journal of Internal Medicine: journal h-index 237 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2014 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 7 / 7 Cited 1,691 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 120.8 citations a year over 14 year(s) since 2014
Impact for its field and year 6 / 6 Cited 55.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 58 other studies in this library
Still being cited 4 / 4 Cited 535 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Laura Fratiglioni: h-index 133 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Cambridge: institution h-index 1,973 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 7 institution(s) in 4 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 24605806)
Free to read 0 / 2 Behind a paywall — scores zero
Total 66 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Petersen, R. C., Caracciolo, B., Brayne, C., Gauthier, S., Jelic, V., & Fratiglioni, L. (2014). Mild cognitive impairment: a concept in evolution. Journal of internal medicine. https://doi.org/10.1111/joim.12190

Vancouver

Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. Journal of internal medicine. 2014. doi:10.1111/joim.12190. PMID: 24605806.

BibTeX

@article{petersen2014-24605806,
  author  = {Petersen, R. C. and Caracciolo, B. and Brayne, C. and Gauthier, S. and Jelic, V. and Fratiglioni, L.},
  title   = {{Mild cognitive impairment: a concept in evolution}},
  journal = {Journal of internal medicine},
  year    = {2014},
  doi     = {10.1111/joim.12190},
  pmid    = {24605806},
  url     = {https://doi.org/10.1111/joim.12190}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 48.

Later studies that cite this one

58 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Mild cognitive impairment

Also tagged “assessment”

840 studies in the library carry the topic tag “assessment”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 840 tagged studies.

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →